PanCryos Company
PANCRYOS is a spin-out arising from the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) at the University of Copenhagen. The company is aiming to develop a next generation stem cell derived allogeneic cell therapy (PanINSULA™) for type 1 diabetes. Based on novel IP, PANCRYOS will – for the first time – enable the definitive safety and large scale manufacturing of insulin cells for therapeutic use. PANCRYOS is in the pre-clinical stage of development and is addressing cost effective scalability and manufacturing of the cell therapy early on to ensure successful commercialization.
Industry:
PharmTech
Headquarters:
Copenhagen, Hovedstaden, Denmark
Zip:
1-10
Founded Date:
2014-01-01
Employees Number:
1-10
Acquisitions Number:
1
Investors Number:
83304
Total Funding:
Less than $1M
Estimated Revenue:
Less than $1M
Last Funding Date:
Grant
Last Funding Type:
Grant
Register and Claim Ownership